Theravance Biopharma 

Theravance Biopharma, Inc. is a biopharmaceutical firm focused on discovering, developing, and bringing to market treatments for respiratory conditions across North America, Europe, and Asia. Its portfolio features YUPELRI, a daily, nebulized long-acting muscarinic antagonist (LAMA) prescribed for chronic obstructive pulmonary disease (COPD). The company also maintains a substantial pipeline of experimental medications. Izencitinib, a gut-targeted pan-janus kinase (JAK) inhibitor, is undergoing Phase IIb/III trials for its potential in treating rheumatoid arthritis, myelofibrosis, and various inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. Ampreloxetine, an investigational norepinephrine reuptake inhibitor, has completed Phase III studies for neurogenic orthostatic hypotension. Another compound, Nezulcitinib, a lung-specific, nebulized JAK inhibitor, is in Phase II clinical development for managing severe lung injury in hospitalized COVID-19 patients. Additionally, Inhaled ALK5i, a promising anti-fibrotic agent delivered via inhalation, is in Phase I for idiopathic pulmonary fibrosis, while TD-5202, an oral, gut-selective, irreversible JAK3 inhibitor, is also in Phase I clinical studies for inflammatory intestinal conditions. Beyond its proprietary offerings, Theravance Biopharma participates in the commercialization of TRELEGY for COPD and asthma, and is involved with Velusetrag and a Selective 5-HT4 Agonist, both investigational oral medications targeting gastrointestinal motility disorders. The company has established licensing and collaboration agreements with prominent pharmaceutical entities, including Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Founded in 2013, Theravance Biopharma, Inc. is headquartered in George Town, Cayman Islands.